Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Pluristem Therapeutics Jumped Over 28% Today

By Maxx Chatsko – Apr 24, 2020 at 2:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.

What happened

Shares of Pluristem Therapeutics (PSTI -9.09%) rose as much as 28.3% today after the company announced it had secured non-dilutive financing from the European Investment Bank (EIB) to support the development of treatments for COVID-19. The stem cell developer is eligible to receive up to $54 million (50 million Euros) in funding in three tranches, with the first $21.5 million expected to be distributed before the end of April. 

Pluristem Therapeutics can receive the second and third installments by achieving certain clinical, regulatory, and manufacturing milestones. It won't have to begin repaying the loan until April 2025. 

As of 1:08 a.m. EDT, the small-cap stock had settled to a 22.9% gain.

A group of ascending arrows on a chalkboard.

Image source: Getty Images.

So what

Today's financing announcement means Pluristem Therapeutics can hit the ground running to develop stem-cell based treatments for COVID-19. Importantly, it also means the company can limit dilutive fundraising transactions to support research and development (R&D) efforts. But investors might still expect a public stock offering to be conducted soon.

Pluristem Therapeutics expects the $54 million financing from EIB to cover up to 50% of R&D expenses related to its COVID-19 project. The business reported only $16 million in cash on its balance sheet at the end of 2019, which means it will need additional funding -- likely raised from public offerings of common stock -- if the project progresses. 

Now what

To be blunt, Pluristem Therapeutics is a stem cell stock that doesn't belong in your portfolio. The company sported a market valuation of only $60 million just a few weeks ago, but has climbed to $225 million on recent announcements that it was developing treatments for COVID-19. While fellow stem-cell developer Mesoblast reported promising results today from a small clinical trial, investors cannot extrapolate that to Pluristem Therapeutics. This remains a very risky stock.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pluristem Therapeutics Inc. Stock Quote
Pluristem Therapeutics Inc.
PSTI
$0.70 (-9.09%) $0.07
Mesoblast Limited Stock Quote
Mesoblast Limited
MESO
$2.80 (-5.08%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.